News >

cfDNA Assay Emerges as Viable Option for MSI Detection

Gina Columbus @ginacolumbusonc
Published: Tuesday, Aug 06, 2019

Martina Lefterova, MD, PhD, laboratory director and medical director at Guardant Health

Martina Lefterova, MD, PhD

Cell-free DNA (cfDNA)-based detection of microsatellite instability (MSI) status was found to be highly concordant with tissue-based MSI testing, according to results of an analysis recently published in Clinical Cancer Research.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x